Kodiak Sciences to Present Novel Glaucoma Treatment at Glaucoma 360 New Horizons Forum 2025

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tre...

February 05, 2025 | Wednesday | News
Grifols Partners with FcR Therapeutics to Develop Nanobodies for Autoimmune Disease Treatment

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines,  announced that it is col...

February 05, 2025 | Wednesday | News
Roche Announces FDA Approval of Susvimo® for Diabetic Macular Edema, Offering a Treatment with Fewer Injections

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced  that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/...

February 05, 2025 | Wednesday | News
Vanda Pharmaceuticals and AnaptysBio Enter Exclusive Global License Agreement for Imsidolimab in GPP Treatment

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) announced an exclusive, global license agreement ...

February 04, 2025 | Tuesday | News
Halozyme's Subcutaneous RYBREVANT® Formulation Receives Positive CHMP Opinion for Advanced NSCLC Treatment

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a...

February 04, 2025 | Tuesday | News
PhaseV Partners with Alimentiv to Revolutionize GI Clinical Trials Using Machine Learning

 PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced  it has entered a strategic partnership with&...

February 04, 2025 | Tuesday | News
HR+/HER2- Breast Cancer Market Sees Growth and Innovation in Treatment Options

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone receptors for estrogen and/or progeste...

February 04, 2025 | Tuesday | News
EMA's CHMP Recommends Opdivo® + Yervoy® for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

 Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

February 03, 2025 | Monday | News
China’s NMPA Approves Sarclisa for Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomid...

February 03, 2025 | Monday | News
Mesoblast Advances U.S. Commercial Launch of Ryoncil® for Pediatric SR-aGvHD, with Key Milestones Ahead

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases,  provided an update on the progres...

January 31, 2025 | Friday | News
Amgen Announces European Commission Approval of BLINCYTO® for Frontline Treatment of B-ALL

Amgen (NASDAQ:AMGN) announced that the European Commission (EC) has approved BLINCYTO® (blinatumomab) monotherapy as part of consolidation therapy...

January 31, 2025 | Friday | News
Datar Cancer Genetics Launches AI-Powered Video Reporting Service for Chemosensitivity Testing

Datar Cancer Genetics (DCG) has launched a revolutionary video reporting service for in vitro chemosensitivity testing, powered by AI-based technology. Thi...

January 29, 2025 | Wednesday | News
European Commission Approves LAZCLUZE® (lazertinib) and RYBREVANT® (amivantamab) for First-Line Treatment of EGFR-Mutant Advanced NSCLC

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has granted marketing authorization (MA) to LA...

January 28, 2025 | Tuesday | News
Neurocrine Biosciences Secures Global Rights to Osavampator, a Potential Breakthrough Treatment for Major Depressive Disorder

 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced it has amended its agreement with Takeda to develop and commercialize osavampator (NB...

January 28, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close